NCT02098720

An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)

An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chengdu Kanghong Biotech Co., Ltd. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the effect of Conbercept therapy on visual acuity and anatomic outcomes and safety observed in subjects with very low vision secondary to wet age-related macular degeneration.

Conditions

• Very Low Vision Secondary to Wet Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Conbercept

Timeline

• Start date: 2011-12-01
• Primary completion: 2014-03-01
• First posted: 2014-03-28
• Last updated: 2014-07-22

Locations

1 site across 1 country: China